The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 31, 2024

Filed:

Dec. 16, 2021
Applicant:

Molecular Templates, Inc., Austin, TX (US);

Inventors:

Eric Poma, New York, NY (US);

Erin Willert, Round Rock, TX (US);

Hilario Ramos, Austin, TX (US);

Jensing Liu, Round Rock, TX (US);

Roger Waltzman, New York, NY (US);

Assignee:

Molecular Templates, Inc., Austin, TX (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 31/7036 (2006.01); A61K 35/74 (2015.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); A61K 9/0019 (2013.01); A61K 31/7036 (2013.01); A61K 35/74 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01);
Abstract

The present disclosure relates to PD-L1-binding molecules comprising a Shiga toxin effector region, a PD-L1-binding region, and a T cell epitope, and pharmaceutical compositions thereof. The PD-L1 binding molecules and pharmaceutical compositions thereof have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells), for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutics for treating or slowing the progression of cancer (e.g., non-small cell lung cancer or squamous cell carcinoma of the head and neck). The present disclosure also relates to clinical methods for use of the disclosed PD-L1 binding molecules for treating a subject in need thereof.


Find Patent Forward Citations

Loading…